Investigational drug · Phase 3
DWP14012
Also called: Fexuprazan
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Healed Erosive Esophagitis, Gastric Ulcer, Helicobacter Pylori Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
30
Any phase or sponsor naming "DWP14012"
First trial start
2024
Feb 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DWP14012", any sponsor or status.
Conditions studied
As listed on its trial records.
- Healed Erosive Esophagitis
- Gastric Ulcer
- Helicobacter Pylori Infection
- Helicobacter Pylori Infected Patients
- Helicobacter Pylori Infected Subjects
Approved drugs for the same conditions: Stomach and esophageal cancer · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "DWP14012" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter PyloriPivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT06751121 · 461 participants · Start Feb 6, 2024 · Primary completion Apr 24, 2025
Drug: DWP14012 40mg; DWC202301 30mg and 4 more · For: Helicobacter Pylori Infection; Helicobacter Pylori Infected Patients; Helicobacter Pylori Infected Subjects
Sites: Seoul, South Korea
- Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic UlcerPivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT04784910 · 423 participants · Start May 21, 2021 · Primary completion Nov 27, 2023
Drug: DWP14012 20mg; Lansoprazole 15 mg and 2 more · For: Peptic Ulcer
Sites: Seoul, South Korea
- Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive EsophagitisPivotal-lookingNot yet recruiting
Daewoong Pharmaceutical Co. LTD.Industry
NCT07746518 · 420 participants (planned) · Start Sep 2026 · Primary completion Aug 2029
Drug: DWP14012 20mg; DWP14012 20 mg placebo and 2 more · For: Healed Erosive Esophagitis
- Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive EsophagitisPivotal-lookingStatus unknown
Daewoong Pharmaceutical Co. LTD.Industry
NCT04341428 · 406 participants (planned) · Start Jul 2, 2020 · Primary completion Aug 30, 2021
Drug: DWP14012 20 mg; DWP14012 20 mg placebo and 2 more · For: Healed Erosive Esophagitis
Sites: Seoul, South Korea
- Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric UlcerPivotal-lookingNot yet recruiting
Daewoong Pharmaceutical Co. LTD.Industry
NCT07730138 · 384 participants (planned) · Start Oct 15, 2026 · Primary completion Apr 15, 2028
Drug: DWP14012 40mg (Fexuprazan); Lansoprazole 30mg · For: Gastric Ulcer
Sites: Jakarta, Indonesia; Incheon, South Korea
- The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux EsophagitisPivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT05813561 · 332 participants · Start Dec 30, 2021 · Primary completion Jul 23, 2022
Drug: DWP14012 · For: Reflux Esophagitis
Sites: Guangzhou, China
- Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux DiseasePivotal-lookingStatus unknown
Daewoong Pharmaceutical Co. LTD.Industry
NCT03811080 · 327 participants (planned) · Start Feb 7, 2019 · Primary completion Feb 2020
Drug: DWP14012 A mg; DWP14012 B mg and 1 more · For: Non-Erosive Gastroesophageal Reflux Disease
Sites: Seoul, South Korea
- Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic GastritisPivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT04341454 · 327 participants · Start Jun 2, 2020 · Primary completion Aug 4, 2021
Drug: DWP14012 X mg; DWP14012 X mg placebo and 2 more · For: Acute Gastritis; Chronic Gastritis
Sites: Seoul, South Korea
- Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)Pivotal-lookingStatus unknown
Daewoong Pharmaceutical Co. LTD.Industry
NCT06121830 · 324 participants (planned) · Start Aug 31, 2023 · Primary completion Jan 2025
Drug: DWP14012 20mg; DWP14012 40mg and 1 more · For: Non-erosive Reflux Disease; Non-Erosive Gastro-Esophageal Reflux Disease; Non-Erosive Esophageal Reflux Disease
Sites: Iksan, South Korea
- Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)Pivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT03736369 · 263 participants · Start Dec 13, 2018 · Primary completion Aug 7, 2019
Drug: DWP14012 40mg; DWP14012 40mg placebo and 2 more · For: Erosive Esophagitis
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Real-World Data on the Efficacy and Safety of Fexuprazan in Patients with Gastroesophageal Reflux Disease: Interim Analysis of Post-Marketing Surveillance.
Kim JH, Lee KH, Lee WS, et al. · Gut Liver 2026
- Efficacy and safety of fexuprazan versus esomeprazole for healing of endoscopic submucosal dissection-induced artificial gastric ulcers: A multicenter, randomized, open-label, active-controlled trial.
Seo GS, Seo SY, Cho JW · Medicine (Baltimore) 2026
- Discovery of highly selective and potent CYP1B1 inhibitors for overcoming paclitaxel resistance in A549/Taxol cells.
Wang T, Fu Y, Song B, et al. · Eur J Med Chem 2026
- The Indian Pharmaceutical Landscape in 2025: CDSCO-Approved Small Molecules and Synthetic Approaches.
Benedetto Tiz D, Bagnoli L, Marini F, et al. · Molecules 2026
- Potassium-Competitive Acid Blockers in GERD and Helicobacter pylori Infection: The Emerging Role of Fexuprazan.
Scarpignato C, Hunt RH · Drugs 2026
- Randomized controlled trial comparing 7-day fexuprazan-based and 14-day rabeprazole-based triple therapies for Helicobacter pylori eradication.
Kim JH, Nam SJ, Kim SH, et al. · Medicine (Baltimore) 2026
Also in development for Healed Erosive Esophagitis
- DWC202517Phase 31 trial
Daewoong Pharmaceutical Co. LTD. · Healed Erosive Esophagitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.